HCPCS Level II code C2698 designates a stranded brachytherapy radioactive source billed per individual source. Brachytherapy sources are critical consumables in radiation oncology for intracavitary and interstitial treatments used across cancer care. Precise coding of these supplies affects claims processing, inventory accounting, and clinical documentation.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national perspective on how this supply code is classified, its typical clinical settings, and the implications for billing lines and reimbursement workflows. The analysis outlines benchmark considerations, payer coverage patterns, and coding practice notes relevant to radiation oncology services that use stranded sources.

This publication provides an operational summary for revenue cycle and clinical teams: what the code represents, where it is used, common billing contexts, and which payers to consider when assessing coverage and claims adjudication. Data not available in the input are noted where applicable. The content is intended for a national audience of health system billing managers, radiation oncology administrators, and policy analysts.